Real-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study

Simple item page
dc.contributor.authorVíctor González-Uribe
dc.contributor.authorHector Rodrigo Pastrana-Ayala
dc.contributor.authorLuis Hernandez-Zarate
dc.contributor.authorCarlos Andrés Gómez-Núñez
dc.contributor.authorMaria Julia Rendon-Salazar
dc.contributor.authorTamara Hernandez-Hernandez
dc.contributor.authorRicardo Martínez-Tenopala
dc.contributor.authorZaira Selene Mojica-Gonzalez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T20:05:03Z
dc.date.available2026-03-22T20:05:03Z
dc.date.issued2026
dc.description.abstractIn this Latin American pediatric cohort, dupilumab achieved marked and sustained improvements in disease severity and quality of life, with a favorable safety profile. This real-world study addresses a regional evidence gap and supports dupilumab as an effective and well-tolerated treatment for moderate-to-severe pediatric AD.
dc.identifier.doi10.15586/aei.v54i2.1402
dc.identifier.urihttps://doi.org/10.15586/aei.v54i2.1402
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/79887
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofAllergologia et Immunopathologia
dc.sourceUniversidad La Salle
dc.subjectDupilumab
dc.subjectMedicine
dc.subjectAtopic dermatitis
dc.subjectSCORAD
dc.subjectQuality of life (healthcare)
dc.subjectObservational study
dc.subjectAdverse effect
dc.subjectDermatology
dc.subjectEczema Area and Severity Index
dc.subjectSeverity of illness
dc.titleReal-world effectiveness and safety of dupilumab in children with atopic dermatitis: a Latin American single-center study
dc.typearticle

Files

Collections

Artículo Científico Publicado